Sangamo Therapeutics (0R1D) Income Statement
Sangamo Therapeutics Income Statement
Last quarter (Q1 2026), Sangamo Therapeutics's total revenue was $1.44M, a decrease of 77.60% from the same quarter last year. In Q1, Sangamo Therapeutics's net income was $-31.00M. See Sangamo Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 39.55M | $ 57.80M | $ 176.23M | $ 111.30M | $ 110.70M | |
| $ 31.95M | $ 57.80M | $ 176.23M | $ 99.19M | $ 110.70M | |
| $ 139.95M | $ 161.77M | $ 450.24M | $ 300.47M | $ 294.04M | |
| Depreciation and Amortization | $ 7.60M | $ 9.36M | $ 22.19M | $ 12.11M | $ 17.64M |
| $ -115.90M | $ -89.09M | $ -96.80M | $ -179.74M | $ -160.35M | |
| $ -108.00M | $ -103.97M | $ -274.00M | $ -201.28M | $ -183.34M | |
| $ -15.50M | $ 5.86M | $ 11.10M | $ 9.43M | $ 5.35M | |
| $ -123.50M | $ -98.11M | $ -262.90M | $ -191.85M | $ -177.99M | |
| $ -122.93M | $ -97.94M | $ -257.83M | $ -192.28M | $ -178.29M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.44 | $ -0.49 | $ -1.48 | $ -1.25 | $ -1.23 |
| Diluted EPS | $ -0.44 | $ -0.49 | $ -1.48 | $ -1.25 | $ -1.23 |
| Weighted Average Shares Outstanding | 280.19M | 201.70M | 174.44M | 154.34M | 144.57M |
| Weighted Average Shares Outstanding (Diluted) | 280.19M | 201.70M | 174.44M | 154.34M | 144.57M |
Currency in USD